XML 34 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements - Additional Information (Detail)
 1 Months Ended 3 Months Ended 38 Months Ended 49 Months Ended
Apr. 02, 2018
Apr. 30, 2018
USD ($)
Target
$ / shares
shares
Feb. 28, 2018
USD ($)
May 31, 2016
USD ($)
Program
$ / shares
shares
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
May 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaboration revenue recognized           $ 4,161,000      
Collaboration and license agreement, deferred revenue current         $ 24,763,000   $ 24,763,000   $ 91,560,000
Pfizer Inc. [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of research programs, counterparty nomination | Program       5          
Research term, description         Under the Pfizer Collaboration Agreement, the parties agreed to collaborate during a four-year research term, which ended by its original terms in May 2020. During the research term, the Company was responsible to use its commercially reasonable efforts to advance up to five programs through to the selection of clinical candidates.        
Revenue recognized           1,300,000      
Pfizer Inc. [Member] | Research Term [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Revenue recognized               $ 18,500,000  
Takeda [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Up-front consideration received   $ 110,000,000.0              
Research, License and Option Agreement [Member] | Pfizer Inc. [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Upfront payment under collaboration agreement       $ 10,000,000.0          
Shares issued under equity agreement | shares       1,875,000          
Equity investment aggregate purchase price       $ 30,000,000.0          
Purchase price per share | $ / shares       $ 16.00          
Collaborative agreement research term       4 years          
Collaboration And License Agreement [Member] | Category One Programs [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Percentage of global costs and potential profits sharing ratio   50.00%              
Collaboration And License Agreement [Member] | Takeda [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Upfront payment under collaboration agreement   $ 110,000,000.0              
Collaboration and license agreement month and year   2018-02              
Fund receivable for research and preclinical activities   $ 60,000,000.0              
Research term under collaboration and license agreement   4 years              
Collaboration agreement commencement date Apr. 02, 2018                
Collaboration agreement termination period 180 days                
Collaboration revenue recognized         $ 0 $ 2,900,000 37,000,000.0    
Collaboration and license agreement, deferred revenue         133,000,000.0   133,000,000.0    
Collaboration and license agreement, deferred revenue current         24,800,000   24,800,000    
Collaboration and license agreement, accounts receivable         $ 30,000,000.0   $ 30,000,000.0    
Collaboration And License Agreement [Member] | Takeda [Member] | Minimum [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Collaboration agreement, committed cash     $ 230,000,000.0            
Collaboration And License Agreement [Member] | Takeda [Member] | Category One Programs [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Percentage of global costs and potential profits sharing ratio   50.00%              
Collaboration And License Agreement [Member] | Takeda [Member] | Category Two Programs [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Fund receivable for research and preclinical activities   $ 60,000,000.0              
Research term under collaboration and license agreement   4 years              
Maximum targets for preclinical programs | Target   6              
Option to reach maximum targets for preclinical programs         any one time        
Collaboration and Share Purchase Agreements [Member] | Takeda [Member]                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Shares issued under equity agreement | shares   1,096,892              
Purchase price per share | $ / shares   $ 54.70              
Proceeds from issuance of ordinary shares, net of offering costs   $ 60,000,000.0              
Equity investment agreement official closure month and year   2018-04